Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer
Science Advances · 16.01.2026 · 12 (3)
DOI: 10.1126/sciadv.ady5324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 16.01.2026. Verfasst von Diwei Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen Univers…. Hauptthemen laut MEDLINE: Alternative Splicing, Lactic Acid, Cancer-Associated Fibroblasts, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Medical Research Foundation.
Abstract (Originalsprache)
Lactate in the tumor microenvironment (TME) is typically generated by cells exhibiting high glycolytic flux, exemplified by tumor cells. However, in glycolysis-low malignancies such as prostate cancer, stroma-derived lactate may drive noncanonical signaling and functions that remain unclear. Here, we identified APCDD1 + cancer-associated fibroblasts (CAFs) as a distinct stromal population that secretes lactate into the TME in response to androgen deprivation therapy (ADT). Lactate uptake by prostate cancer cells induces androgen receptor variant 7 expression, thereby conferring resistance to ADT. Mechanistically, lactate-induced lactylation of the spliceosome component SNRPA at Lys 123 (K123) enhances its recognition of cis-acting elements, increases chromatin binding, and promotes androgen receptor splicing. Targeting lactate transport with monocarboxylate transporter inhibitors effectively restores ADT sensitivity. These findings reveal a metabolic-epigenetic axis linking lactate in the microenvironment to alternative splicing regulation and suggest a promising therapeutic strategy to overcome ADT resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.
- Department of Urology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, Guangdong, China.
- Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
ORCID-Profile: Diwei Zhao, Zijun Mo, Tianyou Zhang, Xinyang Cai, Zhenyu Yang, Dong Chen, Junliang Zhao, Yuanwei Li, Fangjian Zhou, Zhen Li, Yonghong Li, Jun Wang
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangdong Medical Research Foundation
- Outstanding Young Scientific and Technological Talents Development Program of Changsha City
- Health Research Project of Hunan Provincial Health Commission
- Scientific Research Fund of Hunan Provincial Education Department
Zitieren
APA
Zhao, D., Mo, Z., Zhang, T., Cai, X., Yang, Z., Chen, D., Zhao, J., Li, Y., Zhou, F., Li, Z., Li, Y., & Wang, J. (2026). Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. Science Advances, 12(3). https://doi.org/10.1126/sciadv.ady5324
Vancouver
Zhao D, Mo Z, Zhang T, Cai X, Yang Z, Chen D, et al. Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. Science Advances. 2026;12(3). doi:10.1126/sciadv.ady5324
BibTeX
@article{Zhao2026,
author = {Zhao, Diwei and Mo, Zijun and Zhang, Tianyou and Cai, Xinyang and Yang, Zhenyu and Chen, Dong and Zhao, Junliang and Li, Yuanwei and Zhou, Fangjian and Li, Zhen and Li, Yonghong and Wang, Jun},
title = {Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {3},
doi = {10.1126/sciadv.ady5324}
}
EUVIMED